Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 650 | $402,290,186 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 537 | 641.47 | 344,469 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 535 | 616.4 | 329,774 | D |
12 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Finance & CFO | 09 Feb 2024 | Sale | 344 | 950.49 | 326,969 | D |
27 Mar 2023 16:41 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | President and Chief Scientific | 23 Mar 2023 | Sale | 400 | 810.3 | 324,120 | I |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 521 | 618.27 | 322,119 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 550 | 579.85 | 318,918 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 435 | 718.5 | 312,548 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 502 | 619.64 | 311,059 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 382 | 800.55 | 305,810 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 363 | 841.15 | 305,337 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 372 | 812.57 | 302,276 | D |
08 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 07 Nov 2022 | Sale | 404 | 747.2 | 301,869 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 305 | 984 | 300,120 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 303 | 982.29 | 297,634 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 299 | 988.76 | 295,639 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 295 | 980.64 | 289,289 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 500 | 577.07 | 288,535 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 345 | 820.54 | 283,086 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 347 | 802.63 | 278,513 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 281 | 985.72 | 276,987 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 347 | 795.38 | 275,997 | D |
25 Nov 2022 13:07 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 23 Nov 2022 | Sale | 373 | 737.37 | 275,039 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 330 | 803.38 | 265,115 | D |
18 Oct 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 17 Oct 2022 | Sale | 358 | 739.5 | 264,741 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 361 | 728.44 | 262,967 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 424 | 617.43 | 261,790 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 275 | 941.41 | 258,888 | D |
02 Feb 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Feb 2024 | Sale | 273 | 945.61 | 258,152 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | POON CHRISTINE A | Director | 23 Aug 2023 | Sale | 300 | 837.92 | 251,376 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 300 | 837.53 | 251,259 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 250 | 983.91 | 245,978 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 333 | 727.17 | 242,148 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 336 | 719.62 | 241,792 | D |
03 Apr 2024 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Apr 2024 | Sale | 250 | 964.73 | 241,182 | D |
04 Jan 2024 16:17 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 02 Jan 2024 | Sale | 274 | 873.91 | 239,451 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 235 | 982.66 | 230,925 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 315 | 730.57 | 230,130 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 240 | 947.81 | 227,474 | D |
12 Dec 2023 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 11 Dec 2023 | Sale | 270 | 838.44 | 226,379 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 300 | 753.66 | 226,098 | D |
15 May 2024 18:10 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 15 May 2024 | Sale | 228 | 987.46 | 225,141 | D |
30 Dec 2022 16:10 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 28 Dec 2022 | Sale | 311 | 716.08 | 222,701 | D |
03 May 2024 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 May 2024 | Sale | 250 | 889.41 | 222,352 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 321 | 687.9 | 220,816 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 297 | 721.74 | 214,357 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 332 | 644.49 | 213,971 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 226 | 938.13 | 212,017 | D |
26 Dec 2023 16:08 | REGN | REGENERON PHARMACEUTICALS Inc | FENIMORE CHRISTOPHER R. | SVP Controller | 22 Dec 2023 | Sale | 250 | 846.27 | 211,568 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 329 | 642.53 | 211,392 | D |
17 Aug 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 16 Aug 2022 | Sale | 325 | 646.44 | 210,093 | D |
06 Sep 2023 16:03 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Sep 2023 | Sale | 250 | 834.55 | 208,638 | D |
27 Mar 2023 16:41 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | President and Chief Scientific | 23 Mar 2023 | Sale | 254 | 804.38 | 204,313 | I |
27 Mar 2023 16:41 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | President and Chief Scientific | 23 Mar 2023 | Sale | 254 | 800.59 | 203,350 | I |
29 Mar 2023 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 28 Mar 2023 | Sale | 243 | 825.37 | 200,565 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 272 | 722.36 | 196,482 | D |
13 Dec 2022 16:13 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 12 Dec 2022 | Sale | 264 | 730.17 | 192,765 | D |
25 Nov 2022 13:07 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 23 Nov 2022 | Sale | 256 | 745.56 | 190,863 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 267 | 714.42 | 190,750 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 200 | 951.77 | 190,354 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 196 | 968.2 | 189,767 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 23 Aug 2023 | Sale | 223 | 844 | 188,212 | D |
03 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Aug 2023 | Sale | 250 | 744.66 | 186,165 | D |
02 Jun 2023 16:12 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 01 Jun 2023 | Sale | 250 | 736 | 184,000 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 182 | 987.38 | 179,703 | D |
06 Jul 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MCCOURT MARION | EVP Commercial | 03 Jul 2023 | Sale | 250 | 710.09 | 177,522 | D |
15 Mar 2024 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Mar 2024 | Sale | 182 | 951.92 | 173,249 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 300 | 576.73 | 173,019 | D |
12 Dec 2022 16:35 | REGN | REGENERON PHARMACEUTICALS Inc | BASSLER BONNIE L | Director | 08 Dec 2022 | Sale | 218 | 779 | 169,822 | D |
15 Nov 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 14 Nov 2023 | Sale | 204 | 797.79 | 162,749 | D |
16 Nov 2022 16:01 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 15 Nov 2022 | Sale | 222 | 726.48 | 161,279 | D |
08 Sep 2022 16:06 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 06 Sep 2022 | Sale | 273 | 578.25 | 157,862 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 201 | 767.25 | 154,217 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 201 | 766.74 | 154,115 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 200 | 768.11 | 153,622 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 200 | 764.23 | 152,846 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 203 | 752.14 | 152,684 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 200 | 763.19 | 152,638 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 200 | 760.7 | 152,140 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 184 | 821.46 | 151,149 | D |
10 Nov 2022 16:00 | REGN | REGENERON PHARMACEUTICALS Inc | BROWN MICHAEL S | Director | 08 Nov 2022 | Sale | 200 | 754.7 | 150,940 | D |
29 Mar 2023 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 28 Mar 2023 | Sale | 181 | 823.6 | 149,072 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 208 | 698.44 | 145,276 | D |
16 Feb 2024 16:15 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 14 Feb 2024 | Sale | 150 | 948.7 | 142,305 | D |
17 May 2024 17:57 | REGN | REGENERON PHARMACEUTICALS Inc | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 17 May 2024 | Sale | 143 | 980.07 | 140,150 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 167 | 813.66 | 135,881 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 181 | 720.41 | 130,394 | D |
29 Mar 2023 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 28 Mar 2023 | Sale | 157 | 824.54 | 129,453 | D |
30 Dec 2022 16:10 | REGN | REGENERON PHARMACEUTICALS Inc | COLES N ANTHONY | Director | 28 Dec 2022 | Sale | 181 | 707.87 | 128,124 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 155 | 815.97 | 126,475 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 174 | 721.38 | 125,520 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 148 | 839.28 | 124,213 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 120 | 989.14 | 118,697 | D |
29 Mar 2023 16:07 | REGN | REGENERON PHARMACEUTICALS Inc | LANDRY ROBERT E | EVP Finance CFO | 28 Mar 2023 | Sale | 142 | 821.4 | 116,639 | D |
25 Aug 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 24 Aug 2023 | Sale | 138 | 835.67 | 115,322 | D |
13 Sep 2022 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | VAN PLEW DANIEL P | EVP & General Mgr, Industrial | 12 Sep 2022 | Sale | 159 | 719.72 | 114,435 | D |
03 Oct 2022 16:05 | REGN | REGENERON PHARMACEUTICALS Inc | TESSIER-LAVIGNE MARC | Director | 29 Sep 2022 | Sale | 160 | 697.29 | 111,566 | D |
06 Dec 2023 16:02 | REGN | REGENERON PHARMACEUTICALS Inc | MURPHY ANDREW J | EVP Research | 05 Dec 2023 | Sale | 136 | 810.38 | 110,212 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 177 | 620.11 | 109,759 | D |
17 May 2024 16:04 | REGN | REGENERON PHARMACEUTICALS Inc | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 15 May 2024 | Sale | 111 | 965.69 | 107,192 | D |
08 Aug 2022 16:11 | REGN | REGENERON PHARMACEUTICALS Inc | STAHL NEIL | EVP Research and Development | 05 Aug 2022 | Sale | 176 | 606.78 | 106,793 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)